Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 106Neoplasms 14Neoplasm Metastasis 14Carcinoma, Non-Small-Cell Lung 4Advanced Breast Cancer 4Hereditary Sensory and Autonomic Neuropathies 3Recurrence 2Prostatic Neoplasms 2Ovarian Neoplasms 2Multiple Endocrine Neoplasia Type 1 2Endometrial Neoplasms 2Breast Neoplasms, Male 2Uterine Neoplasms 1Uterine Cervical Neoplasms 1Urologic Neoplasms 1Triple Negative Breast Neoplasms 1Stomach Neoplasms 1Solid Malignancies 1Recurrent Uterine Corpus Carcinoma 1Neoplasms by Site 1Lymphoma, Non-Hodgkin 1Lymphoma 1Locally Advanced (Inoperable) or Metastatic Breast Cancer 1Lethal Congenital Contracture Syndrome 2 1Hyperglycemia 1Hormone Receptor Positive HER-2 Negative Breast Cancer 1Hormone Receptor Positive Breast Cancer 1HER2-positive Breast Cancer 1Female Breast Carcinoma 1Exanthema 1

Interventions

seribantumab 2zenocutuzumab 1exemestane 1Vinorelbine 1Trastuzumab 1Letrozole 1Fulvestrant 1Erlotinib Hydrochloride 1Anastrozole 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Lethal Congenital Contracture Syndrome 2 × Fulvestrant × Clear all
NCT03321981 2024-03-07

MCLA-128 With Trastuzumab/Chemotherapy in HER2+ and With Endocrine Therapy in ER+ and Low HER2 Breast Cancer.

Merus B.V.

Phase 2 Completed
105 enrolled 23 charts

Lethal Congenital Contracture Syndrome 2

Data powered by HemOnc (CC BY 4.0) Colophon âš¡